Menu

CME Corner

Active Programs

The Pharmacist's Role in Advanced or Metastatic Breast Cancer

Cyclin-dependent kinase (CDK) 4/6 inhibition significantly prolongs progression-free survival (PFS) in patients with metastatic breast cancer (mBRCA) whose disease progresses on endocrine therapies. This activity will examine emerging evidence and best practices supporting the use of CDK4/6 inhibitors. This activity was originally presented as a webcast series on the following 4 dates: February ...

  • Online Presentation Online Presentation
  • ACPE

Evolving Standards of Care in Metastatic Prostate Cancer

For patients with metastatic prostate cancer (mPRCA), the number of metastases has prognostic and therapeutic implications. Clinicians who treat patients with mPRCA need to recognize patients with oligometastatic prostate cancer and be aware that management of patients with fewer than 5 metastases is different from that of patients with polymetastatic disease. Recommendations for the initial manag ...

  • Online Presentation Online Presentation
  • ACCME

Metastatic Colorectal Cancer: Applying Evidence-based Recommendations for Evaluation and Management

Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will e ...

  • Online Presentation Online Presentation
  • ACCME
  • ANCC

Improving Outcomes in Advanced Gastric Cancer: The Latest Updates in Treatment Strategies and Clinical Research

An estimated 26,370 Americans will be diagnosed with gastric cancer in 2016. Most patients with gastric cancer present with advanced or metastatic disease, for which the prognosis is poor. The 5-year survival rate of patients with all stages of gastric cancer in the United States is approximately 29% and drops into the single digits for patients with stage III or IV disease. However, recent advanc ...

  • Mobile + Online on QuantiaMD
  • ACCME

Expired Programs

Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma

The treatment landscape for multiple myeloma (MM) is rapidly evolving. This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma. ...

  • Online Presentation Online Presentation
  • ACCME

Patient-Centered Care in Advanced Prostate Cancer

Recommended treatment options for prostate cancer vary based on disease severity and life expectancy, with traditional approaches including active surveillance, surgery, radiation therapy, chemotherapy, and androgen deprivation therapy (ADT). Prostate cancer that progresses despite ADT is known as castration-resistant prostate cancer (CRPC). Until recently, the standard of care for CRPC patients w ...

  • Mobile + Online on QuantiaMD Mobile + Online on QuantiaMD
  • ACCME

Updates on Molecular Testing in NSCLC

Oncologists have new options when treating advanced NSCLC. The use of molecular profiling to define subgroups of patients most likely to experience clinical benefit from novel targeted therapies has been endorsed by both ASCO and the National Comprehensive Cancer Network (NCCN).This activity will examine the role of molecular biomarkers in patients with advanced NSCLC. ...

  • Mobile + Online on QuantiaMD
  • ACCME
Main Menu
EDITOR'S PICKS